Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Teclistamab-based induction in TE NDMM shows MRD- CR rate 91.8% (45/49) by pre-maintenance timepoint, 100% in evaluable samples and post-induction cycle 3 (10-5 (46/46)), 6 (10-5 (46/46) and 10-6 (46/46)); ORR was 100%.”
Title: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial
Authors: Marc Raab, Niels Weinhold, K. Martin Kortüm, Jan Krönke, Roland Fenk, Katja Weisel, Lilli Podola, Uta Bertsch, Alexander Brobeil, Julia Mersi, Stefanie Huhn, Ryan Arlinghaus, Michael Hundemer, Stephan Bohl, Elias Mai, Natalie Schub, Johannes Waldschmidt, Florian Bassermann, Carsten Müller-Tidow, Christoph Heuck, Caline Sakabedoyan, Josephine Khan, Elena Ershova, Bas Koster, Monika Engelhardt, Mathias Hänel, Hans Salwender, Raphael Teipel, Hartmut Goldschmidt, Hermann Einsele, Leo Rasche
You can read the Full Article on Nature Medicine.
You can find other articles featuring Robert Orlowski on OncoDaily.
